EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1

Liang Qian, Ruyue Ni, Ping Lv, Yuxing Chai, Annoor Awadasseid iD, Xuqiong Xiong, Wen Zhang iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202500972 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2026. Verfasst von Liang Qian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, China. Hauptthemen laut MEDLINE: Small Molecule Libraries, B7-H1 Antigen, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 119 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Leading Innovation and Entrepreneurship Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐based drugs targeting the PD‐1/PD‐L1 axis have become widely used in clinical treatments. However, challenges such as high costs and suboptimal clinical response rates have fueled growing interest in developing small‐molecule inhibitors. Recent clinical trials, both domestically and internationally, have evaluated several small‐molecule inhibitors. Notable compounds like CA‐170 and INCB086550 have shown promising properties and potential in these studies. Although no small‐molecule inhibitors targeting PD‐L1 have yet been approved for clinical use, the path to their development and clinical translation is fraught with challenges. Researchers are actively exploring innovative strategies for drug design and synthesis, while carefully assessing critical factors such as safety and efficacy. Given the essential role of the PD‐1/PD‐L1 pathway in immune evasion by tumors, this review provides a concise overview of the signaling and structure of PD‐1/PD‐L1, summarizes current progress on clinical candidate drugs targeting this pathway, discusses the challenges in translating small‐molecule inhibitors to clinical practice, and outlines future directions in drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Molecule LibrariesB7-H1 AntigenAntineoplastic AgentsHumansProgrammed Cell Death 1 ReceptorAnimalsMolecular Structure

Stichwörter der Autor:innen

PD‐1/PD‐L1 pathwayclinical translationdrug developmentimmune evasionsmall‐molecule inhibitors

Substanzen

Small Molecule LibrariesB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorAntineoplastic Agents

Autor:innen und Institutionen

  • Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, China.
  • Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, China.
  • Kecheng Industrial Development Institute, Zhejiang University of Technology, Quzhou, China.
  • Zhejiang Jieyuan Med-Tech Co., Ltd., Hangzhou, China.

ORCID-Profile: Annoor Awadasseid, Wen Zhang

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Leading Innovation and Entrepreneurship Team

Zitieren

APA

Qian, L., Ni, R., Lv, P., Chai, Y., Awadasseid, A., Xiong, X., & Zhang, W. (2026). Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1. ChemMedChem. https://doi.org/10.1002/cmdc.202500972

Vancouver

Qian L, Ni R, Lv P, Chai Y, Awadasseid A, Xiong X, et al. Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1. ChemMedChem. 2026. doi:10.1002/cmdc.202500972

BibTeX
@article{Qian2026,
  author = {Qian, Liang and Ni, Ruyue and Lv, Ping and Chai, Yuxing and Awadasseid, Annoor and Xiong, Xuqiong and Zhang, Wen},
  title = {Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202500972}
}
Kostenlos starten →